Stockscreener 앱 받기
49.43
1.98%
0.96
시간 외 거래:
49.44
0.010
+0.02%
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
Maze Therapeutics (NASDAQ:MAZE) Upgraded to "Strong-Buy" at Truist Financial - MarketBeat
Truist Securities initiates coverage of Maze Therapeutics (MAZE) with buy recommendation - MSN
Fundamentals Check: What analysts say about Maze Therapeutics Inc stockEarnings Growth Summary & Weekly High Potential Stock Alerts - baoquankhu1.vn
This Evommune analyst begins coverage on a bullish note; here are top 5 initiations for Wednesday - MSN
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Truist initiates Maze Therapeutics stock coverage with buy rating By Investing.com - Investing.com Canada
Maze Therapeutics (NASDAQ:MAZE) Sets New 1-Year High After Analyst Upgrade - Defense World
Maze Therapeutics (NASDAQ:MAZE) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Foresite Capital Management IV LLC Sells 1,589,262 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Foresite Capital Management V LLC Sells 258,900 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics, Inc. News — NASDAQ:MAZE - TradingView
Boothbay Fund Management LLC Acquires 276,345 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
545,132 Shares in Maze Therapeutics, Inc. $MAZE Acquired by ArrowMark Colorado Holdings LLC - MarketBeat
Maze Therapeutics stock hits all-time high at 49.28 USD By Investing.com - Investing.com Nigeria
Maze Therapeutics (NASDAQ:MAZE) Upgraded at Mizuho - Defense World
Assessing Maze Therapeutics (MAZE) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Maze Therapeutics (NASDAQ:MAZE) Rating Increased to Strong-Buy at Mizuho - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) CMO Sells 30,000 Shares - MarketBeat
Maze Therapeutics Executive Sells All Common Stock Holdings - TradingView
Maze Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Maze Therapeutics stock hits all-time high at 49.28 USD - Investing.com Australia
Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month HighShould You Buy? - MarketBeat
Analysts’ Top Healthcare Picks: Acurx Pharmaceuticals (ACXP), Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Mizuho initiates coverage of Maze Therapeutics (MAZE) with outperform recommendation - MSN
Maze Therapeutics (NASDAQ:MAZE) Shares Up 8.5%Here's Why - MarketBeat
Why Maze Therapeutics Stock Is Suddenly Surging - TipRanks
This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Mizuho Initiates Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Mizuho initiates Maze Therapeutics stock with Outperform rating By Investing.com - Investing.com Canada
Maze Therapeutics’ (MAZE) “Buy” Rating Reaffirmed at BTIG Research - Defense World
Underappreciated Cardiometabolic Upside: Validating Maze’s SLC6A19 Inhibitor MZE782 and Supporting a Buy on MAZE - TipRanks
Maze Therapeutics' (MAZE) "Buy" Rating Reiterated at BTIG Research - MarketBeat
Maze Therapeutics, Inc. (MAZE) Gets a Buy from Leerink Partners - The Globe and Mail
Buy Rating on Maze Therapeutics: Favorable HORIZON Phase 2 Setup, Validated APOL1 Biology, and Underappreciated Pipeline Upside - TipRanks
MAZE: Lead kidney and metabolic disease programs advance toward pivotal data with strong financial backing - TradingView
Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up Following Analyst Upgrade - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Given New $58.00 Price Target at Guggenheim - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Sees Significant Growth in Short Interest - MarketBeat
Aug Update: What analysts say about Maze Therapeutics Inc stockWeekly Profit Recap & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Pullback Watch: Is Iveda Solutions Inc a good ESG investmentMarket Weekly Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Maze Therapeutics, Inc. (MAZE) Stock Analysis: Biotech Innovator with a 10.77% Potential Upside - DirectorsTalk Interviews
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
Maze Therapeutics Inc CEO set for TD Cowen Health Care event - Traders Union
MAZE Technical Analysis & ETF Price Forecast - Intellectia AI
Buy Rating on Maze Therapeutics Driven by MZE829’s Differentiated APOL1 Mechanism and HORIZON UACR-Reduction Catalyst - TipRanks
Maze Therapeutics, Inc. (MAZE) Stock Analysis: A Biotech With A 9.78% Upside Potential - DirectorsTalk Interviews
Is Maze Therapeutics Inc. forming bullish engulfing patterns2025 Year in Review & Stepwise Entry and Exit Trade Signals - mfd.ru
Latest MAZE ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
Zifo Partners With Maze Therapeutics on Managing Biobank Data - Contract Pharma
Zifo and Maze Therapeutics Partner to Power Precision Medicine - The Malaysian Reserve
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge - AOL.com
Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Earnings Recap: How liquid is Maze Therapeutics Inc stockQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge - The Motley Fool
Maze Therapeutics Stock Just Shot Up 24% Pre-Market Today – Here’s What Happened - MSN
MAZE Should I Buy - Intellectia AI
Maze Therapeutics (MAZE) Valuation Check After Strong 1 Year Shareholder Return - Yahoo Finance
1.20%
0.06%
자본화:
|
볼륨(24시간):